[1]
Aarsland D, Kramberger MG. Neuropsychiatric symptoms in Parkinson’s disease. J Parkinsons Dis 2015; 5(3): 659-67.
[2]
Berg D, Postuma RB, Adler CH, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015; 30(12): 1600-11.
[3]
Castrioto A, Thobois S, Carnicella S, Maillet A, Krack P. Emotional manifestations of PD: Neurobiological basis. Mov Disord 2016; 31(8): 1103-13.
[4]
Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: An update. Lancet Neurol 2017; 16(3): 238-50.
[5]
Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol 2017; 13(2): 81-95.
[6]
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008; 23(2): 183-9.
[7]
Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci 2017; 18(7): 435-50.
[8]
Broen MP, Narayen NE, Kuijf ML, Dissanayaka NN, Leentjens AF. Prevalence of anxiety in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord 2016; 31(8): 1125-33.
[9]
Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson’s disease. Brain 2016; 139(11): 2827-43.
[10]
Bartoli F, Pompili M, Lillia N, et al. Rates and correlates of suicidal ideation among stroke survivors: A meta-analysis. J Neurol Neurosurg Psychiatry 2017; 88(6): 498-504.
[11]
Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: A systematic review of current literature. J Psychosom Res 2012; 73(6): 411-7.
[12]
Berman AL, Silverman MM, Bongar BM. Comprehensive textbook of suicidology. 2nd ed. New York: Guilford Press 2000.
[13]
Lewis DS, Anderson KH, Feuchtinger J. Suicide prevention in neurology patients: Evidence to guide practice. J Neurosci Nurs 2014; 46(4): 241-8.
[14]
Pompili M, Forte A, Berman AL, Lamis DA. The association between physical illness/medical conditions and suicide risk. In: The International Handbook of Suicide Prevention. 2nd ed. Wiley & Sons, Ltd, Chichester 2016; pp. 133-48.
[15]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: b2700.
[16]
Stenager EN, Wermuth L, Stenager E, Boldsen J. Suicide in patients with Parkinson’s disease. An epidemiological study. Acta Psychiatr Scand 1994; 90(1): 70-2.
[17]
Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 2001; 14(3): 120-4.
[18]
Nazem S, Siderowf AD, Duda JE, et al. Suicidal and death ideation in Parkinson’s disease. Mov Disord 2008; 23(11): 1573-9.
[19]
Kummer A, Cardoso F, Teixeira AL. Suicidal ideation in Parkinson’s disease. CNS Spectr 2009; 14(8): 431-6.
[20]
Mainio A, Karvonen K, Hakko H, Särkioja T, Räsänen P. Parkinson’s disease and suicide: A profile of suicide victims with Parkinson’s disease in a population-based study during the years 1988-2002 in Northern Finland. Int J Geriatr Psychiatry 2009; 24(9): 916-20.
[21]
Kostić VS, Pekmezović T, Tomić A, et al. Suicide and suicidal ideation in Parkinson’s disease. J Neurol Sci 2010; 289(1-2): 40-3.
[22]
Lee T, Lee HB, Ahn MH, et al. Increased suicide risk and clinical correlates of suicide among patients with Parkinson’s disease. Parkinsonism Relat Disord 2016; 32: 102-7.
[23]
Berardelli I, Belvisi D, Corigliano V, et al. Suicidal ideation, perceived disability, hopelessness and affective temperaments in patients affected by Parkinson’s disease. Int J Clin Pract 2018; 73(3)e13287
[25]
Li W, Abbas MM, Acharyya S, et al. Suicide in Parkinson’s disease. Mov Disord Clin Pract (Hoboken) 2018; 5(2): 177-82.
[26]
Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. Lancet Neurol 2012; 11(5): 429-42.
[27]
Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson’s disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002; 72(6): 701-7.
[28]
Soulas T, Gurruchaga JM, Palfi S, Cesaro P, Nguyen JP, Fénelon G. Attempted and completed suicides after subthalamic nucleus stimulation for Parkinson’s disease. J Neurol Neurosurg Psychiatry 2008; 79(8): 952-4.
[29]
Voon V, Krack P, Lang AE, et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease. Brain 2008; 131(Pt 10): 2720-8.
[30]
Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 2003; 349(20): 1925-34.
[31]
Burkhard PR, Vingerhoets FJ, Berney A, Bogousslavsky J, Villemure JG, Ghika J. Suicide after successful deep brain stimulation for movement disorders. Neurology 2004; 63(11): 2170-2.
[32]
Funkiewiez A, Ardouin C, Cools R, et al. Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson’s disease. Mov Disord 2006; 21(10): 1656-62.
[33]
Lhommée E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson’s disease: Restoring the balance of motivated behaviours. Brain 2012; 135(Pt 5): 1463-77.
[35]
Strutt AM, Simpson R, Jankovic J, York MK. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson’s disease. Eur J Neurol 2012; 19(1): 121-7.
[36]
Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: A randomised, multicentre study. Lancet Neurol 2008; 7(7): 605-14.
[37]
Weintraub D, Duda JE, Carlson K, et al. Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson’s disease: results from a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2013; 84(10): 1113-8.
[38]
Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 2010; 362(22): 2077-91.
[39]
Weaver FM, Follett KA, Stern M, et al. Randomized trial of deep brain stimulation for Parkinson disease: Thirty-six-month outcomes. Neurology 2012; 79(1): 55-65.
[40]
Boel JA, Odekerken VJ, Schmand BA, et al. Cognitive and psychiatric outcome 3 years after globus pallidus pars interna or subthalamic nucleus deep brain stimulation for Parkinson’s disease. Parkinsonism Relat Disord 2016; 33: 90-5.
[41]
Lhommée E, Wojtecki L, Czernecki V, et al. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial): Secondary analysis of an open-label randomised trial. Lancet Neurol 2018; 17(3): 223-31.
[42]
Pompili M. The increase of suicide rates: The need for a paradigm shift. Lancet 2018; 392(10146): 474-5.
[43]
Sauerbier A, Cova I, Rosa-Grilo M, Taddei RN, Mischley LK, Chaudhuri KR. Treatment of nonmotor symptoms in Parkinson’s disease. Int Rev Neurobiol 2017; 132: 361-79.
[44]
Mills KA, Greene MC, Dezube R, Goodson C, Karmarkar T, Pontone GM. Efficacy and tolerability of antidepressants in Parkinson’s disease: A systematic review and network meta-analysis. Int J Geriatr Psychiatry 2018; 33(4): 642-51.
[45]
Berardelli I, Bloise MC, Bologna M, et al. Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson’s disease. Neuropsychiatr Dis Treat 2018; 14: 399-405.
[46]
Shepard MD, Perepezko K, Broen MPG, et al. Suicide in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2019; 90(7): 822-9.
[47]
Pompili M. Exploring the phenomenology of suicide. Suicide Life Threat Behav 2010; 40(3): 234-44.
[48]
Pompili M. Phenomenology of suicide. Cham, Switzerland: Springer Nature 2017.
[49]
Webb RT, Kontopantelis E, Doran T, Qin P, Creed F, Kapur N. Suicide risk in primary care patients with major physical diseases: A case-control study. Arch Gen Psychiatry 2012; 69(3): 256-64.
[50]
Lewis DS, Anderson KH, Feuchtinger J. Suicide prevention in neurology patients: Evidence to guide practice. J Neurosci Nurs 2014; 46(4): 241-8.
[51]
Eliasen A, Dalhoff KP, Horwitz H. Neurological diseases and risk of suicide attempt: A case-control study. J Neurol 2018; 265(6): 1303-9.
[52]
Serafini G, Calcagno P, Lester D, Girardi P, Amore M, Pompili M. Suicide risk in Alzheimer’s disease: A systematic review. Curr Alzheimer Res 2016; 13(10): 1083-99.
[53]
Du L, Zeng J, Liu H, et al. Fronto-limbic disconnection in depressed patients with suicidal ideation: A resting-state functional connectivity study. J Affect Disord 2017; 215: 213-7.
[54]
Tremblay L, Worbe Y, Thobois S, Sgambato-Faure V, Féger J. Selective dysfunction of basal ganglia subterritories: From movement to behavioral disorders. Mov Disord 2015; 30(9): 1155-70.
[55]
Mitchell JE, Crosby R, de Zwaan M, et al. Possible risk factors for increased suicide following bariatric surgery. Obesity (Silver Spring) 2013; 21(4): 665-72.
[56]
Peterhänsel C, Petroff D, Klinitzke G, Kersting A, Wagner B. Risk of completed suicide after bariatric surgery: A systematic review. Obes Rev 2013; 14(5): 369-82.
[57]
Manoloudakis N, Labiris G, Karakitsou N, Kim JB, Sheena Y, Niakas D. Characteristics of women who have had cosmetic breast implants that could be associated with increased suicide risk: A systematic review, proposing a suicide prevention model. Arch Plast Surg 2015; 42(2): 131-42.
[58]
Pompili M, Girardi P, Tatarelli G, Angeletti G, Tatarelli R. Suicide after surgical treatment in patients with epilepsy: A meta-analytic investigation. Psychol Rep 2006; 98(2): 323-38.
[59]
Foncke EM, Schuurman PR, Speelman JD. Suicide after deep brain stimulation of the internal globus pallidus for dystonia. Neurology 2006; 66(1): 142-3.
[60]
Thobois S, Ardouin C, Lhommée E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: Predictors and underlying mesolimbic denervation. Brain 2010; 133(Pt 4): 1111-27.
[61]
Cyron D. Mental side effects of deep brain stimulation (DBS) for movement disorders: The futility of denial. Front Integr Nuerosci 2016; 10: 17.
[62]
Temel Y, Tan S, Visser-Vandewalle V, Sharp T. Parkinson’s disease, DBS and suicide: a role for serotonin? Brain 2009; 132(Pt 10)e126
[63]
Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003; 4(10): 819-28.
[64]
Cowen PJ. Serotonin and depression: Pathophysiological mechanism or marketing myth? Trends Pharmacol Sci 2008; 29(9): 433-6.
[65]
Hershey T, Revilla FJ, Wernle A, Gibson PS, Dowling JL, Perlmutter JS. Stimulation of STN impairs aspects of cognitive control in PD. Neurology 2004; 62(7): 1110-4.
[66]
Temel Y, Blokland A, Steinbusch HW, Visser-Vandewalle V. The functional role of the subthalamic nucleus in cognitive and limbic circuits. Prog Neurobiol 2005; 76(6): 393-413.
[67]
Frank MJ, Samanta J, Moustafa AA, Sherman SJ. Hold your horses: Impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007; 318(5854): 1309-12.
[68]
Combs HL, Folley BS, Berry DT, et al. Cognition and depression following deep brain stimulation of the subthalamic nucleus and globus pallidus pars internus in Parkinson’s disease: A meta-analysis. Neuropsychol Rev 2015; 25(4): 439-54.
[69]
Wang XH, Zhang L, Sperry L, et al. Target selection recommendations based on impact of deep brain stimulation surgeries on nonmotor symptoms of parkinson’s disease. Chin Med J (Engl) 2015; 128(24): 3371-80.
[70]
Jęśko H, Wencel P, Strosznajder RP, Strosznajder JB. Sirtuins and their roles in brain aging and neurodegenerative disorders. Neurochem Res 2017; 42(3): 876-90.
[71]
Singh P, Hanson PS, Morris CM. SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease. BMC Neurosci 2017; 18(1): 46.
[72]
Nivoli A, Porcelli S, Albani D, et al. Association between sirtuin 1 gene rs10997870 polymorphism and suicide behaviors in bipolar disorder. Neuropsychobiology 2016; 74(1): 1-7.
[73]
Lu G, Li J, Zhang H, Zhao X, Yan LJ, Yang X. Role and possible mechanisms of sirt1 in depression. Oxid Med Cell Longev 2018; 20188596903
[74]
Martins IJ. Heat shock gene inactivation and protein aggregation with links to chronic diseases. Diseases 2018; 6(2): 1-5.
[75]
Martins IJ. Electroconvulsive therapy and heat shock gene inactivation in neurodegenerative diseases. Ann Neurodegener Dis 2018; p. 1028.
[76]
Martins IJ. Brain stimulation therapies in neuropsychiatric and neurodegenerative diseases. Int J Genom Data Min 2018; p. 1.
85
12
1
1